MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
shares upon follow-on...
$205,390K
Proceeds from exercise of
stock options
$8,391K
Proceeds from borrowings
under credit facility...
$3,000K
Proceeds from issuance of
common stock under...
$1,030K
Net cash provided by
financing activities
$211,297K
Canceled cashflow
$6,514K
Net (decrease)
increase in cash and cash...
-$91,179K
Canceled cashflow
$211,297K
Maturities of marketable
securities
$344,962K
Stock-based compensation
expense, including...
$17,586K
Other current
liabilities
$10,984K
Accounts payable
$4,598K
Non-cash lease expense
$1,176K
Depreciation and
amortization expense
$490K
Payment of issuance
costs for shares...
$6,514K
Net cash used in
investing activities
-$155,760K
Canceled cashflow
$344,962K
Net cash used in
operating activities
-$146,716K
Canceled cashflow
$34,834K
Purchases of marketable
securities
$500,722K
Net loss
-$162,451K
Non-cash interest income
on marketable...
-$6,292K
Other assets and
long-term deposits
$6,145K
Prepaid expenses and
other current assets
$5,418K
Operating lease
liabilities
-$1,244K
Back
Back
Cash Flow
source: myfinsight.com
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)